Labcorp Holdings Inc.

• LH Stock Price 24h change: -0.80%. From 271.31 USD to 269.14 USD.
• From a technical perspective, LH presents a "bullish consolidation" pattern. The stock remains in a long-term uptrend, trading near its 52-week highs (range: $209.38 - $293.72), with technical signals leaning toward a "Strong Buy." However, short-term momentum shows a slight pullback as the market digests recent gains ahead of the upcoming earnings report.
• Labcorp expanded its molecular residual disease (MRD) testing portfolio with new assays for early cancer recurrence detection, strengthening its position in precision oncology.
• The Board approved a quarterly cash dividend of $0.72 per share, payable on March 12, 2026, signaling consistent capital returns to shareholders.
• Labcorp announced it will release its fourth-quarter and full-year 2025 financial results before the market opens on February 17, 2026.
• The global medical image management market is projected to reach $10.2 billion by 2033, driven by a 9.8% CAGR and increasing demand for AI-enabled diagnostics and digital interoperability.
• Cybersecurity concerns in the healthcare sector intensified following a January 2026 cyberattack that disrupted clinical services at a major hospital, highlighting vulnerabilities in interconnected medical data systems.

• LH Stock Price 24h change: +0.16%. From 270.87 USD to 271.31 USD.
• From a technical perspective, LH is currently in a "short-term bullish recovery": the stock has recently moved above its 20-day and 50-day moving averages, supported by a positive MACD crossover. However, with an RSI near 65, it is approaching overbought territory, suggesting potential resistance near the 275 USD level.
• Labcorp recently expanded its Minimal Residual Disease (MRD) testing capabilities to improve recurrence risk monitoring for breast, lung, and colon cancer patients.
• The company declared a quarterly dividend of $0.72 per share and announced it will release its fourth-quarter 2025 financial results on February 17, 2026.
• Labcorp presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting strategic acquisitions and high-growth therapeutic partnerships to drive future margin improvements.
• Lucid Diagnostics was awarded a U.S. Department of Veterans Affairs contract to supply its EsoGuard Esophageal DNA Test, expanding access to over 9 million veterans.
• Avanos Medical and Siemens Healthineers announced a co-marketing agreement to integrate imaging and radiofrequency technologies for outpatient pain care across U.S. surgical centers.